HF
ADAP

HRT Financial’s Adaptimmune Therapeutics ADAP Stock Holding History

HRT Financial’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-83,199
Closed -$44K – 2453
2024
Q4 		$44K Buy
+83,199
New +$60.6K ﹤0.01% 2124
2024
Q1 		– Sell
-59,906
Closed -$47K – 2212
2023
Q4 		$47K Buy
+59,906
New +$33.8K ﹤0.01% 1962
2023
Q2 		– Sell
-18,047
Closed -$19K – 2367
2023
Q1 		$19K Buy
+18,047
New +$28K ﹤0.01% 2186
2022
Q3 		– Sell
-21,091
Closed -$35K – 2713
2022
Q2 		$35K Buy
+21,091
New +$36.2K ﹤0.01% 2546
2021
Q3 		– Sell
-42,621
Closed -$181K – 3218
2021
Q2 		$181K Buy
+42,621
New +$207K ﹤0.01% 2424
2020
Q1 		– Sell
-44,245
Closed -$53K – 723
2019
Q4 		$53K Buy
+44,245
New +$47.2K ﹤0.01% 1066

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HRT Financial's ADAP Position: Q1 2025 in Review

HRT Financial sold out of Adaptimmune Therapeutics (ADAP) in Q1 2025, closing a stake of 83,199 shares — an estimated $44K sold.

HRT Financial first reported a position in ADAP in Q4 2019 and held it in 6 quarters. The position peaked at $181K in Q2 2021. 67 funds tracked by Wall St. Rank hold ADAP as of Q1 2025.

  • HRT Financial reported no remaining Adaptimmune Therapeutics position as of Q1 2025 after selling out during the quarter.
  • HRT Financial sold 83,199 Adaptimmune Therapeutics shares in Q1 2025, an estimated $44K.
  • HRT Financial first reported a position in Adaptimmune Therapeutics in Q4 2019 and held it in 6 quarters.
  • HRT Financial's Adaptimmune Therapeutics position peaked at $181K in Q2 2021.
  • 67 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2025.

Based on HRT Financial's 13F filing for Q1 2025, filed 15 May 2025.